CVD

Semiconductor Grade Ammonia Market Size to Grow USD 681.5 Million by 2030 at a CAGR of 6.2% | Valuates Reports

Retrieved on: 
Wednesday, February 14, 2024

The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.

Key Points: 
  • The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-34U16199/Global_Se...
    The ongoing rise of the semiconductor sector, which requires ultra-pure chemicals for production processes, is the main factor driving the market for semiconductor grade ammonia.
  • Because of its strict quality standards, semiconductor grade ammonia is essential to maintaining the dependability and functionality of electronic components.
  • The need for semiconductor grade ammonia is rising due to the semiconductor industry's constant innovation and growth.

Semiconductor Grade Ammonia Market Size to Grow USD 681.5 Million by 2030 at a CAGR of 6.2% | Valuates Reports

Retrieved on: 
Wednesday, February 14, 2024

The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.

Key Points: 
  • The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-34U16199/Global_Se...
    The ongoing rise of the semiconductor sector, which requires ultra-pure chemicals for production processes, is the main factor driving the market for semiconductor grade ammonia.
  • Because of its strict quality standards, semiconductor grade ammonia is essential to maintaining the dependability and functionality of electronic components.
  • The need for semiconductor grade ammonia is rising due to the semiconductor industry's constant innovation and growth.

Buchanan Obtains Preliminary Win with International Trade Commission's Affirmative Determination in Trade Cases on Wine Bottles from Chile, China, and Mexico

Retrieved on: 
Monday, February 12, 2024

The Commission's unanimous affirmative vote comes in response to petitions filed December 29, 2023, by the U.S. Glass Producers Coalition.

Key Points: 
  • The Commission's unanimous affirmative vote comes in response to petitions filed December 29, 2023, by the U.S. Glass Producers Coalition.
  • The petitions allege that unfairly dumped and subsidized wine bottles are injuring the domestic industry.
  • The Commission's affirmative preliminary injury determination paves the way for the Department of Commerce to move forward with its investigations.
  • Commerce is expected to issue its preliminary CVD determination in March 2024 and its preliminary AD determinations in June 2024.

Nudj Health Expands Virtual Cardiac Rehab Services to Patients with Ornish Lifestyle Medicine by Sharecare

Retrieved on: 
Tuesday, February 6, 2024

Nudj Cardiac Complete, in partnership with Ornish Lifestyle Medicine by Sharecare, allows physician groups to provide cardiac rehab to patients at home thus increasing access, adoption and adherence to cardiac rehabilitation.

Key Points: 
  • Nudj Cardiac Complete, in partnership with Ornish Lifestyle Medicine by Sharecare, allows physician groups to provide cardiac rehab to patients at home thus increasing access, adoption and adherence to cardiac rehabilitation.
  • Nudj is increasing access, adoption and adherence to these vital cardiac rehab services and enabling physicians to meet their patients no matter where they are on their health journey.
  • Nudj Cardiac Complete includes three major care pathway service offerings:
    Cardiac Wellness/Risk Reduction: Using the evidence-based model of Collaborative Care, the Nudj Health American College of Lifestyle Medicine (ACLM) certified program delivers lifestyle and behavioral health modifications every month to patients.
  • I’m pleased that Nudj Health will now offer my intensive cardiac rehabilitation program virtually,” said Dean Ornish, M.D., founder of Ornish Lifestyle Medicine.

Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eye

Retrieved on: 
Monday, February 5, 2024

Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology.
  • The CLAiR technology integrates readily with existing retinal cameras, to provide real-time CVD risk assessments with accuracy comparable to gold standard cardiovascular risk assessments (which typically require blood tests and can take weeks).
  • The AI-powered CLAiR technology identifies elevated cardiovascular risk by analyzing minute changes in the retina and its vasculature.
  • CLAiR will enable healthcare providers in various settings to identify elevated cardiovascular risk in adult patients with no known history of cardiovascular disease.

CDC Foundation's Live to the Beat campaign spotlights cardiovascular disease in Black women, issuing a call-to-action to help Black women prioritize self-care for their own heart health

Retrieved on: 
Thursday, February 1, 2024

Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.

Key Points: 
  • Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.
  • CDC Foundation's Live to the Beat campaign is launching a "Heart2Heart Challenge" to encourage Black women to give themselves permission to prioritize self-care for their own heart health.
  • "Black women are the figurative heartbeats of Black families and communities, but many of their own hearts are in trouble.
  • Now entering its third year, the CDC Foundation's Live to the Beat campaign is CDC's first national cardiovascular disease prevention campaign developed for the Black community.

Genomics plc publishes clinical trial results demonstrating successful integration and clinical utility of integrated risk scores combining polygenic and clinical risk of cardiovascular disease in NHS primary care

Retrieved on: 
Wednesday, January 31, 2024

The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.

Key Points: 
  • The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.
  • It was designed to evaluate an integrated risk tool (IRT) that combines genetic risk in the form of a polygenic risk score or PRS, with QRISK, a prediction algorithm for CVD.
  • For people aged 45-64, genetics accounts for 40% as much risk as all the non-genetic risk factors combined in QRISK.
  • We hope that it will also encourage similar studies incorporating genetics into clinical risk prediction for other common diseases."

New Survey Reveals 86 Percent of Benefits Leaders Recognize Need for Heart Health Strategy in 2024

Retrieved on: 
Tuesday, January 23, 2024

Hello Heart , the digital leader in preventive heart health, today released its inaugural Why Heart Health Matters Report , which examines the toll that cardiovascular disease (CVD) takes on employers, health plans, and the people they serve.

Key Points: 
  • Hello Heart , the digital leader in preventive heart health, today released its inaugural Why Heart Health Matters Report , which examines the toll that cardiovascular disease (CVD) takes on employers, health plans, and the people they serve.
  • The report surveyed 300 benefits leaders at large employers and health plans to gauge their investment and prioritization of member health initiatives for 2024.
  • As a result, organizations increasingly recognize heart health as a business need, with 76 percent listing it among their top three strategic organizational health priorities for 2024.
  • The Why Heart Health Matters Report shows that 86 percent of benefits leaders at large employers and health plans recognize the need for an organizational strategy to address heart health.

Supportive, Stable Caregiving in Childhood Protects Heart Health in Adulthood

Retrieved on: 
Tuesday, January 23, 2024

New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.

Key Points: 
  • New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.
  • "At the same time, our findings show that adversity in early childhood does not equal destiny.
  • While adverse childhood family environments were associated with lower odds of cardiovascular health in adulthood, our findings suggest that supportive and, importantly, stable caregiving may have a stronger influence on later heart health than early adversity."
  • The hope, says Ortiz, is that this study offers insight into how supporting healthy, both supportive and stable, caregiving relationships in childhood can offer greater attainment of CVH at a population level.

CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL

Retrieved on: 
Monday, January 22, 2024

HOUSTON, Jan. 22, 2024 /PRNewswire/ -- Texas Children's Hospital announces today that Biological E's CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding Domain (RBD) protein of SARS-CoV-2 engineered by Texas Children's Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine (BCM),

Key Points: 
  • "The recombinant yeast strains enable production of the RBD protein which can be further utilized by vaccine researchers globally to develop & manufacture effective and low-cost vaccines.
  • By providing access to the yeast strains via non-exclusive licensing, we continue our mission to support global vaccine accessibility and availability."
  • Biological E subsequently developed large scale manufacturing technology for production of the RBD protein complying with Good Manufacturing Practices (GMP) as well as testing & characterization suitable for use as vaccine antigen.
  • The RBD protein was then used as an antigen and formulated with optimized adjuvants (Alum and CpG1018) to develop a COVID-19 candidate vaccine.